OR WAIT null SECS
September 15, 2026
Article
Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.
September 08, 2026
Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.
September 05, 2026
Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.
August 31, 2026
Video
Christie Ballantyne, MD, unpacks SHASTA-3/4 results on plozasiran for severe hypertriglyceridemia, from triglyceride reduction to pancreatitis prevention.
August 30, 2026
SHASTA-3 and SHASTA-4 found plozasiran cut triglycerides by roughly 80% and acute pancreatitis events by 78% in severe hypertriglyceridemia.
Ashish Sarraju, MD, discusses phase 1 data showing a single dose of Kylo-11 durably reduced lipoprotein(a) through 48 weeks.
August 29, 2026
A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.
New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.
Steven Nissen, MD, shares key takeaways on AAV8, CTX310, and Kylo-11 gene and molecular therapies presented at ESC Congress 2026.
CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.
